The Series D round of financing announced Tuesday was led by General Atlantic. Boston-based Biofourmis employs artificial intelligence and machine-learning techniques to analyze patient physiological ...

AI-backed remote monitoring and digital therapeutics company Biofourmis raised a whopping $300 million in Series D funding, boosting the company to unicorn status with a valuation of $1.3 billion. The ...

AdventHealth has partnered with Biofourmis to introduce the AdventHealth Hospital at Home programme, which offers inpatient-level care to patients within their own homes. This innovative initiative ...

AI-backed remote monitoring and digital therapeutics company Biofourmis added another $20 million to its Series D round, bringing its raise to $320 million. The extension funding comes from Intel ...

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in ...

Biofourmis is collaborating with Lee Health's Epic EHR system to guarantee smooth management of both acute and post-acute care. Credit: TippaPatt/Shutterstock. Biofourmis, a global care delivery ...

Biofourmis, a digital therapeutics company, is rolling out an artificial intelligence-driven remote monitoring solution nationally. The solution, Biovitals Hospital@Home, was co-developed with Brigham ...

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Biofourmis, an AI health IT company based in Boston, today announced it ...

Biofourmis, a developer of digital therapeutics aimed at personalized care, says its technology is being used in a remote-monitoring and disease-surveillance program in Hong Kong involving patients ...

Boston-based digital therapeutics (DTx) provider Biofourmis on Monday revealed that it both struck a deal with pharma giant Novartis to commercialize a DTx for monitoring heart failure patients and ...

Biofourmis, a startup developing digital therapeutics and artificial intelligence to remotely monitor patients, said its valuation hit $1.3 billion after raising a $300 million Series D funding round ...